Journals and News
The latest publications and news on the ongoing activity at Sus Clinicals.
The Oncopig Cancer Model: An Innovative Large Animal Translational Oncology Platform
Cancer is a global epidemic causing more than 8 million annual deaths worldwide. The more than 13 million new cancer diagnoses made each year carry an economic burden of $290B. Cancer is expected to be the second leading cause of death in the United States in 2017. The American Cancer Society (ACS) estimates approximately 1,688,780 new cancer diagnoses will be made and 600,920 Americans will die from cancer.
Translating Human Cancer Sequences Into Personalized Porcine Cancer Models
The global incidence of cancer is rapidly rising, and despite an improved understanding of cancer molecular biology, immune landscapes, and advancements in cytotoxic, biologic, and immunologic anti-cancer therapeutics, cancer remains a leading cause of death worldwide.
Oncopig Soft-Tissue Sarcomas Recapitulate Key Transcriptional Features of Human Sarcomas
Human soft-tissue sarcomas (STS) are rare mesenchymal tumors with a 5-year survival rate of 50%, highlighting the need for further STS research. Research has been hampered by limited human sarcoma cell line availability and the large number of STS subtypes, making development of STS cell lines and animal models representative of the diverse human STS subtypes critical. Pigs represent ideal human disease models due to their similar size, anatomy, metabolism, and genetics compared to humans.
Development and Comprehensive Characterization of Porcine Hepatocellular Carcinoma for Translational Liver Cancer Investigation
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide. New animal models that faithfully recapitulate human HCC phenotypes are required to address unmet clinical needs and advance standard-of-care therapeutics. This study utilized the Oncopig Cancer Model to develop a translational porcine HCC model which can serve as a bridge between murine studies and human clinical practice. Reliable development of Oncopig HCC cell lines was demonstrated through hepatocyte isolation and Cre recombinase exposure across 15 Oncopigs.
Porcine Cancer Models: Potential Tools to Enhance Cancer Drug Trials
: The amount of time and money invested into cancer drug research, development, and clinical trials has continually increased over the past few decades. Despite record high cancer drug approval rates, cancer remains a leading cause of death. This suggests the need for more effective tools to help bring novel therapies to clinical practice in a timely manner.
The Oncopig Cancer Model as a Complementary Tool for Phenotypic Drug Discovery
The screening of potential therapeutic compounds using phenotypic drug discovery (PDD) is being embraced once again by researchers and pharmaceutical companies as an approach to enhance the development of new effective therapeutics. Before the genomics and molecular biology era and the consecutive emergence of targeted-drug discovery approaches, PDD was the most common platform used for drug discovery.
Of Mice, Dogs, Pigs, and Men: Choosing the Appropriate Model for Immuno-Oncology Research
Cancer has recently surpassed cardiovascular diseases as the leading cause of death worldwide. The increasing cancer incidence combined with the emergence of improved therapeutic strategies has driven research into fields such as how the immune system Influences cancer development and progression. The term immunosurveillance has traditionally been used to describe how the immune system can protect the host from tumor development.